Cancer Prevention and Control Committee

Purpose

The NRG NCORP Cancer Prevention and Control (CPC) Committee prioritizes interventional studies designed to improve the symptom burden from cancer and its treatment, or to prevent cancer or morbidity from cancer and its treatment.

Research priorities and focus areas include: improving neurocognition; reducing sex-specific symptoms (lymphedema, sexual dysfunction, etc.); behavioral interventions to mitigate symptoms or cancer risk; therapeutic delivery modifications and/or agents to improve symptoms, quality of life, and cost-effectiveness; and, prevention through optimal screening, risk reduction, or chemoprevention. 

The goal of the NRG NCORP CPC Committee is to generate high impact research that prevents and finds cancers early and improves the health of cancer survivors. We accomplish this through interdisciplinary team science and strong collaboration with NRG’s Health Care Access and Disease-Site Committees. As such, our committee membership is intentionally multidisciplinary (discipline; research focus; MD, PhD, RN, APP, patient advocates; academic and community; all career levels) with an important focus in mentoring the next generation of CPC clinician scientists. Committee members have the opportunity to serve as liaisons to the Disease-site Committees, review new concepts and to become co-investigators on developing trials. 

This committee meets monthly.

Cancer Prevention and Control Committee Leadership

Chair

Tracey Crane, PhD

Chair

Julie Bauman, MD

Vice Chair

Mylin Torres, MD

Vice Chair

Stephanie V. Blank, MD
Core Committee Members

  • Jinbing Bai
  • Hanna Bandos
  • Emma L. Barber
  • Julie Baumann
  • Jennifer Bea
  • Beth Beadle
  • Stephanie Blank
  • Jeanne Carter
  • Reena Cecchini
  • Pavani Chalasani
  • Tracy Crane
  • Danielle Enserro
  • Britt Erickson
  • Carolyn Fang
  • David S. Goldberg
  • Vinai Gondi
  • Ragisha Gopalakrishnan 
  • Elizabeth Hile
  • Warner Huh
  • Megan L. G. Hutchcraft
  • Lisa Kachnic
  • Melin J. Khandekar
  • Jordan Kharofa
  • Yelena E. Kier
  • Rachel Kupets
  • Lindsay Kuroki
  • Olivia Lara
  • Simon Lo
  • Deborah C. Marshall
  • Kathryn A. Mills
  • Julie Nangia
  • Sagar A. Patel
  • Kathryn Pennington
  • Laurel Pracht
  • Stephanie Pugh
  • Jose Alejandro Rauh-Hain
  • Kristin Redmond
  • Stephanie M. Rieder
  • Lindsay Romak
  • Diane Rose
  • Aasma Shaukat
  • Siddharth H. Sheth
  • Shivani Sud
  • Mylin Torres
  • Christina M. Wilson
  • Kathleen Yost

Resources


CPC Pre-LOI Form

NCORP Concept Development and Evaluation Forms

 

 

Reset all column filters
Study Title Status Phase Disease Category Disease Site
NRG-CC001

A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients with Brain Metastases

 Terminated III Symptom Management [CC] Other
NRG-CC003

Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer

 Terminated II/III Symptom Management [CC] Other
NRG-CC004

Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire in Women with Breast or Gynecologic Cancer

 Complete II Symptom Management [CC] Other
NRG-CC005

FORTE (Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps)

 Open to Accrual III Prevention [CC] Colorectal
NRG-CC008

A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]

 Open to Accrual Other Prevention [CC] Ovarian
NRG-CC009

Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for Brain Metastases from Small Cell Lung Cancer

 Open to Accrual III Symptom Management [CC] Other
NRG-CC011

Cognitive Training For Cancer Related Cognitive Impairment In Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial

 Temporarily Closed to Accrual III Symptom Management [CC] Other
NRG-CC013

A Randomized, Masked, Placebo Controlled, Phase II Trial Of Concurrent Chemoradiation With BMX-001 In Patients With Head And Neck Squamous Cell Carcinoma Receiving Concurrent Chemoradiation

 Open to Accrual II Head and Neck [HN] Other
NRG-CC014

Radiation Therapy for High-Risk Asymptomatic Bone Metastases: A Pragmatic Multicenter Randomized Phase 3 Clinical Trial (PREEMPT)

 Open to Accrual III Symptom Management [CC] Bone Metastases
NRG-CC015

Harnessing E-Mindfulness Approaches for Living After Breast Cancer — HEAL-ABC

 Open to Accrual III Symptom Management [CC] Breast
RTOG-0631

Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis

 Terminated II/III Symptom Management [CC] Other

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.